Ana I. Velázquez Mañana, MD MSc (she/her/ella)(@AnaVManana) 's Twitter Profileg
Ana I. Velázquez Mañana, MD MSc (she/her/ella)

@AnaVManana

Thoracic Onc @UCSFCancer @ZSFGCare | Boricua🇵🇷 Clinical Trial Disparities, Health Equity, DEIA @LatinXOncology | 🎓@medupr @uprm @NCSP_UCSF Views are mine

ID:979744921056768000

linkhttps://coi.asco.org/share/GXF-G67R/Ana%20Velazquez%20Manana calendar_today30-03-2018 15:39:26

12,0K Tweets

5,8K Followers

5,3K Following

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation(@RManochakian) 's Twitter Profile Photo

🚨🔥OncoAlert Hot off the Press.

New by ASCO & @IntegrativeOnc on:

“Management of -related during & after cancer treatment.”

is a very common & distressing symptom in with .
We CAN HELP them.

👇🏼
brnw.ch/21wJRao

🚨🔥@OncoAlert Hot off the Press. New #Guidelines by @ASCO & @IntegrativeOnc on: “Management of #Cancer-related #Fatigue during & after cancer treatment.” #Fatigue is a very common & distressing symptom in #Patients with #Cancer. We CAN HELP them. 👇🏼 brnw.ch/21wJRao
account_circle
GRACE(@cancerGRACE) 's Twitter Profile Photo

Meet Dr. María Velez Velez!

Dr. Maria Antonia Vélez research interests span from developmental therapeutics in thoracic oncology and head and neck cancer to identify approaches in which investigators can enhance diversity and inclusion of historically underrepresented racial and ethnic

Meet Dr. María Velez Velez! Dr. @MomaVelez11 research interests span from developmental therapeutics in thoracic oncology and head and neck cancer to identify approaches in which investigators can enhance diversity and inclusion of historically underrepresented racial and ethnic
account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Dr. Marina Garassino with a concise and balanced editorial NEJM on CheckMate 77T and the perioperative immunotherapy approach for resectable NSCLC. Impressive results, but who benefits from the adjuvant portion specifically?

nejm.org/doi/full/10.10…

account_circle
Joshua Reuss(@Joshua_Reuss) 's Twitter Profile Photo

Dr. Jennifer Marks, MD breaks down latest data for Trastuzumab Deruxtecan in HER2-overexpressing solid tumors including NSCLC at . Rapidly evolving space & need more prospective data to ID pts most likely to respond such as concurrent HER2 amp. Georgetown Lombardi

Dr. @jennifermarksmd breaks down latest data for Trastuzumab Deruxtecan in HER2-overexpressing solid tumors including NSCLC at #LungCancerSymposium. Rapidly evolving space & need more prospective data to ID pts most likely to respond such as concurrent HER2 amp. @LombardiCancer
account_circle
Dr. Estela Rodriguez(@Latinamd) 's Twitter Profile Photo

Why are we smiling😁? Because we like our jobs in academia and got invited to speak about it at the place to be during : The ASCO TECAG Trainee Lounge

Join us for this Panel Discussion on Careers in Oncology Academia with Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute Amanda Nizam, MD

Why are we smiling😁? Because we like our jobs in academia and got invited to speak about it at the place to be during #ASCO24: The @ASCOTECAG Trainee Lounge Join us for this Panel Discussion on Careers in Oncology Academia with @neerajaiims @huntsmancancer @AmandaNizamMD
account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Matched pair cohort study of NSCLC Clinical Lung Cancer again shows that if PD(L)1 inhibitors are given before EGFR TKIs, higher risk of pneumonitis and higher in-hospital mortality. Seen with various EGFR TKIs. Reminder to wait for biomarker results!
clinical-lung-cancer.com/article/S1525-…

account_circle
EGFR Resisters(@EGFRResisters) 's Twitter Profile Photo

Efficacy and safety of EGFR-TKI combined with WBRT vs. WBRT alone in the treatment of brain mets

In contrast to WBRT alone, the combination of EGFR-TKI and WBRT significantly improves intracranial response, enhancing the ORR, DCR, & 1 year survival rate.

frontiersin.org/journals/neuro…

account_circle
D. Ross Camidge(@DRCamidge) 's Twitter Profile Photo

Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!

Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!
account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Disappointing results from phase 3 CheckMate 73L study of concurrent nivolumab + chemoradiation for stage III NSCLC & nivol +/- ipilimumab vs durvalumab consolidation. No improvement in PFS over standard PACIFIC approach. Similar to negative PACIFIC-2.

news.bms.com/news/corporate…

account_circle
Arya Roy(@royaryam) 's Twitter Profile Photo

Grateful to be selected as a Patient Education Ambassador! Excited to collaborate with GRACE, learn from experienced members & work towards our goal of improving education! H. Jack West, MD Amy Bickleman Ivy Riano, M.D. ASCO TECAG IMG Oncologists Roswell Park

account_circle